Clinicopathological Features and Survival of Young Turkish Patients with Testicular Germ Cell Tumors

Ozgun, Alpaslan; Karagöz, Bülent; Tuncel, Tolga; Emirzeoglu, Levent; Celi̇k, Serkan; Bilgi, Oğuz

doi:10.7314/apjcp.2013.14.11.6889

Cited by 9 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same order of frequency has been reported in Japan, yet with different proportions relative to MGCT (76.3%), embryonic carcinoma (11.6%) and malignant teratoma (5.7%) (Miki et al, 2014). The predominance of mixed germ cell tumors among nonseminomatous tumors has also been reported in Turkey (Ozgun et al, 2013). Few studies have approached the subject of distribution of non-seminomatous tumors, probably due to limited clinical or therapeutic impact.…”

Section: Discussionmentioning

confidence: 54%

Distribution of Testicular Tumors in Lebanon: A Single Institution Overview

Assi

Rassy²,

Nassereddine³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Testicular tumors constitute a rare type of cancer affecting adolescents and young adults with recent reports confirming an increase in incidence worldwide. The purpose of this study was to estimate the epidemiological characteristics and histological subtypes of testicular tumors in the Lebanese population according to the WHO classification of testicular and paratesticular tumors. Materials and Methods: In this single institutional retrospective study, all patients diagnosed with a testicular tumor in Hotel-Dieu de France Hospital University in Beirut between 1992 and 2014 were enrolled. The age, subtype based on the 2004 WHO classification and body side of tumor were analyzed. Results: A total of two hundred and forty-four (244) patients diagnosed with a testicular tumor in our institution were included in the study. Two hundred and one patients (82.4% of all testicular tumors) had germ cell tumors (TGCT). Among TGCT, 50% were seminomatous tumors, 48% non-seminomatous tumors (NST) and 2% were spermatocytic seminomas. The NST were further divided into mixed germ cell tumors (63.9%), embryonic carcinomas (18.6%), teratomas (15.4%) and yolk sac tumors (2.1%). The mean age for testicular tumors was 32 years. The mean age for germ cell tumors was 31 years and further subtypes such as seminomatous tumors had a mean age of 34 years, 28 years in non-seminomatous tumors and 56 years in spermatocytic seminoma. Patients with right testicular tumor were the predominant group with 55% of patients. Three patients (1.2%) presented with bilateral tumors. Conclusions: The distribution of different subgroups and the mean age for testicular tumors proved comparable to most countries of the world except for some Asian countries. Germ cell tumors are the most common subtype of testicular tumors with seminomatous tumors being slightly more prevalent than non-seminomatous tumors in Lebanese patients.

show abstract

Section: Discussionmentioning

confidence: 54%

Distribution of Testicular Tumors in Lebanon: A Single Institution Overview

Assi

Rassy²,

Nassereddine³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The 2-year OS rate was 100% for patients with stage I disease, 94% for those with stage II disease, and 70.2% for those with stage III disease. 16…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil

Vasconcellos

Bastos

Pereira

et al. 2019

JGO

View full text Add to dashboard Cite

PURPOSE Reported treatment outcomes for patients with advanced germ cell tumors (aGCT) are based mainly on series from developed nations. Data from low- and middle-income countries are underrepresented. MATERIAL AND METHODS From 2000 to 2015, a retrospective analysis identified 300 patients with aGCT treated at our institution. Kaplan-Meier methods were used for analysis of progression-free survival (PFS) and overall survival (OS) according to the International Germ Cell Consensus Classification Group (IGCCCG). RESULTS Patients’ median age was 28 years. According to the IGCCCG, 57% had good-, 18.3% intermediate-, and 24.7% poor-risk disease. Median α-fetoprotein levels were 2.9, 243, and 3,998 ng/mL, and those of human chorionic gonadotropin were 0.4, 113, and 301.5 mUI/mL in IGCCCG good-, intermediate-, and poor-risk groups, respectively. At a median 46 months of follow-up, 93 PFS events and 45 deaths had occurred and estimated 5-year PFS and OS were 69% and 85%, respectively, including 83% and 95.3% in good-risk, 70.9% and 83.6% in intermediate-risk, and 35.1% and 62.2% in poor-risk patients, respectively. In multivariable analysis, Eastern Cooperative Oncology Group performance status ≥ 2 was a significant independent prognostic factor with a hazard ratio of 2.58 (95% CI, 1.55 to 4.29; P < .001) and 6.20 (95% CI, 2.97 to 12.92; P < .001) for PFS and OS, respectively. CONCLUSION Brazilian patients with aGCT in this cohort had similar outcomes as patients in the IGCCCG database. In comparison with contemporary series, patients with intermediate- and poor-risk aGCT had slightly inferior PFS and OS, possibly due to a high percentage of patients with poor performance status and less use of high-dose chemotherapy.

show abstract

“…In this study, the frequency of promoter methylation of eight candidate genes ( MGMT, CALCA , VGF, HOXA9, NANOG , CDKN2B, CDO1 and ADAMTS1 ) was evaluated to assess a set of potential biomarkers that would accurately discriminate clinical outcome of patients with TGCT. A significant proportion of TGCT patients (15-25%) presents refractory disease, which results in a poor outcome [ 17 , 18 ]. Therefore, efforts to identify new molecular prognostic markers are essential in TGCT, especially for these refractory patients [ 19 ].…”

Section: Discussionmentioning

confidence: 99%